ArticleOncotarget2016

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

Sedef Iskit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.